Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AxV-128/Tc SPECT-CT for Perioperative Lung Injury
NCT02978885Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Jun 2018
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of technetium-tc99m-labeled annexin a5 in acute lung injury (ALI) (2 arms), sponsored by Columbia University. Primary endpoints: Correlation of AxV-128/Tc Uptake and Fibrinogen at 1 week, Correlation of AxV-128/Tc Uptake and C-Reactive Protein at 1 week and 1 more. Started Jun 2018; status: terminated.
02
Drugs
technetium-tc99m-labeled annexin a5
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT02978885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02978885.